Circulating apoptotic markers in the management of non-small cell lung cancer

Cancer Biomarkers

Volumn 6, Issue 3-4, 2009, Pages 197-210

  Holdenrieder, Stefan ^a   Stieber, Petra ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

apoptosis; cancer; caspases; CD95; Cell death; CYFRA 21 1; cytokeratins; diagnosis; DNA; M30; nucleosomes; plasma; prognosis; serum; sFas; TPA; TPS; tumor

Indexed keywords

ADENOSINE TRIPHOSPHATE; BH3 PROTEIN; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CYTOCHROME C; CYTOKERATIN 18; CYTOKERATIN 19 FRAGMENT; DNA; FAS ANTIGEN; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROCASPASE 9; PROTEIN BCL 2; PROTEIN BID; PROTEIN P53; RAS PROTEIN; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER; TUMOR NECROSIS FACTOR RECEPTOR 1;

APOPTOSIS; CD8+ T LYMPHOCYTE; COLON POLYPOSIS; HUMAN; IMMUNE RESPONSE; IMMUNOPHENOTYPING; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77958168664     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2009-0130     Document Type: Review

References (200)

1. J. M. Adams and S. Cory, The Bcl-2 protein family: arbiters of cell survival, Science 281 (1998), 1322-1326.
2. S. Ando, H. Kimura, N. Iwai, N. Yamamoto and T. Iida, Positive reactions for both Cyfra21-1 and CA125 indicate worst prognosis in non-small cell lung cancer, Anticancer Res 23 (2003), 2869-2874.
3. F. Andriani, D. Conte, T. Mastrangelo, M. Leon, C. Ratcliffe, L. Roz, G. Pelosi, P. Goldstraw, G. Sozzi and U. Pastorino, Detecting lung cancer in plasma with the use of multiple genetic markers, Int J Cancer 108 (2004), 91-96.
4. P. Anker and M. Stroun, Tumor-related alterations in circulating DNA, potential for diagnosis, prognosis and detection of minimal residual disease, Leukemia 15 (2001), 289-291.
5. T. Aotake, C. D. Lu, Y. Chiba, R. Muraoka and N. Tanigawa, Changes of angiogenesis and tumor cell apoptosis during colorectal carcinogenesis, Clin Cancer Res 5 (1999), 135-142.
6. A. Ashkenazi and V. M. Dixit, Death receptors: signaling and modulation, Science 281 (1998), 1305-1308.
7. H. Bai, L. Mao, H. S. Wang, J. Zhao, L. Yang, T. T. An, X. Wang, C. J. Duan, N. M. Wu, Z. Q. Guo, Y. X. Liu, H. N. Liu, Y. Y. Wang and J. Wang, Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer, J Clin Oncol 27 (2009), 2653-2659.
8. V. Barak, H. Goike, K. W. Panaretakis and R. Einarsson, Clinical utility of cytokeratins as tumor markers, Clin Biochem 37 (2004), 529-540.
9. V. Barak, S. Holdenrieder and P. Stieber, Relevance of circulating biomarkers for the therapy monitoring and followup investigations in patients with non-small cell lung cancer, Cancer Biomark 6 (2010), 191-196.
10. F. Barlesi, C. Gimenez, J. P. Torre, C. Doddoli, J. Mancini, L. Greillier, F. Roux and J. P. Kleisbauer, Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer, Respir Med 98 (2004), 357-362.
11. F. Barlesi, G. Giaccone, M. I. Gallegos-Ruiz, A. Loundou, S. W. Span, P. Lefesvre, F. A. E. Kruyt and J. A. Rodriguez, Global histone modifications predict prognosis of resected non-small cell lung cancer, J Clin Oncol 25 (2007), 4358-4364.
12. K. Barczyk, M. Kreuter, J. Pryjma, E. P. Booy, S. Maddika, S. Ghavami, W. E. Berdel, J. Roth and M. Los, Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy, Int J Cancer 116 (2005), 167-173.
13. J. Bates, R. Rutherford, M. Divilly, J. Finn, H. Grimes, I. O'Muircheartaigh and J. J. Gilmartin, Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer, Eur Respir J 10 (1997), 2535-2538.
14. S. H. Beachy and E. A. Repasky, Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update, Cancer Immunol Immunother 57 (2008), 759-775.
15. M. Bewick, M. Conlon, A. M. Parissenti, H. Lee, L. Zhang, S. Gluck and R. M. Lafrenie, Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation, J Hematother Stem Cell Res 10 (2001), 759-768. (Pubitemid 34081304)
16. J. L. Boddy, S. Gal, P. R. Malone, A. L. Harris and J. S. Wainscoat, Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease, Clin Cancer Res 11 (2005), 1394-1399.
17. H. Bodenmueller, B. Ofenloch-Haehnle, E. B. Lane, A. Dessauer, V. Bottger and F. Donie, Lung cancer-associated keratin 19 fragments: development and biochemical characterisation of the new serum assay Enzymun-Test CYFRA 21-1, Int J Biol Markers 9 (1994), 75-81.
18. J. M. Bonfrer, K. N. Gaarenstroom, G. G. Kenter, C. M. Korse, A. A. Hart, M. P. Gallee, T. J. Helmerhorst and P. Kenemans, Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer, Gynecol Oncol 55 (1994), 371-375.
19. R. M. Bremnes, R. Sirera and C. Camps, Circulating tumourderived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer 49 (2005), 1-12.
20. J. G. Brockmann, H. St Nottberg, B. Glodny, A. Heinecke and N. J. Senninger, CYFRA 21-1 serum analysis in patients with esophageal cancer, Clin Cancer Res 6 (2000), 4249-4252.
21. G. Buccheri and D. Ferrigno, Lung tumor markers of cytokeratin origin: an overview, Lung Cancer 34 (2001), S65-S69.
22. I. Budihardjo, H. Oliver, M. Lutter, X. Luo and X. Wang, Biochemical pathways of caspase activation during apoptosis, Annu Rev Cell Dev Biol 15 (1999), 269-290.
23. J. Cummings, T. H. Ward, M. Ranson and C. Dive, Apoptosis pathway-targeted drugs-from the bench to the clinic, Biochim Biophys Acta 1705 (2004), 53-66.
24. E. C. De Haas, A. di Pietro, K. L. Simpson, C. Meijer, A. J. Suurmeijer, L. J. Lancashire, J. Cummings, S. de Jong, E. G. de Vries, C. Dive and J. A. Gietema, Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer, Neoplasia 10 (2008), 1041-1048.
25. U. Deligezer, N. Erten, E. E. Akisik and N. Dalay, Circulating fragmented nucleosomal DNA and caspase-3 mRNA in patients with lymphoma and myeloma, Exp Mol Pathol 80 (2006), 72-76.
26. Y. F. Deng, P. Chen, Y. Z. Lin, J. Z. Le, X. L. Wu, M. Q. Yu, P. Y. Zhuang and M. H. Gao, Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma, J Laryngol Otol 117 (2003), 190-194.
27. D. Derin, H. O. Soydinç, N. Guney, F. Tas, H. Camlica, D. Duranyildiz, V. Yasasever and E. Topuz, Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer, Lung Cancer 59 (2008), 240-245.
28. C. Du, M. Fang, Y. Li, L. Li and X. Wang, Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition, Cell 102 (2000), 33-42.
29. W. Ebert, H. Dienemann, A. Fateh-Moghadam, M. Scheulen, N. Konietzko, T. Schleich and E. Bombardieri, Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron specific enolase in lung cancer. Results of an international multicentre study, Eur J Clin Chem Clin Biochem 32 (1994), 189-199. (Pubitemid 24096845)
30. W. Ebert and T. Muley, CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy, Anticancer Res 19 (1999), 2669-2672.
31. M. Enari, H. Sakahira, H. Yokoyama, K. Okawa, A. Iwamatsu and S. Nagata, A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD, Nature 391 (1998), 43-50.
32. M. Esteller, Cancer epigenomics: DNA methylomes and histone-modification maps, Nature Rev Genet 8 (2007), 286-298.
33. B. Fadeel, S. Orrenius and B. Zhivotovsky, Apoptosis in human disease: a new skin for the old ceremony? Biochem Biophys Res Commun 266 (1999), 699-717.
34. B. Fadeel and S. Orrenius, Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease, J Intern Med 258 (2005), 479-517.
35. D. Ferrigno, G. Buccheri and C. Giordano, Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC), Lung Cancer 41 (2003), 311-320.
36. M. Fleischhacker and B. Schmidt, Circulating nucleic acids (CNAs) and cancer-a survey, Biochim Biophys Acta 1775 (2007), 181-232.
37. M. Fleischhacker and B. Schmidt, Free circulating nucleic acids inplasma and serum (CNAPS)-useful for the detection of lung cancer patients? Cancer Biomark 6 (2010), 211-219.
38. G. J. Fournie, J. P. Courtin, F. Laval, J. J. Chale, J. P. Pourrat, M. C. Pujazon, D. Lauque and P. Carles, Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours, Cancer Lett 91 (1995), 221-227.
39. S. Gal, C. Fidler, Y. M. Lo, M. Taylor, C. Han, J. Moore, A. L. Harris and J. S. Wainscoat, Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR, Br J Cancer 90 (2004), 1211-1215.
40. O. Gautschi, C. Bigosch, B. Huegli, M. Jermann, A. Marx, E. Chasse, D. Ratschiller, W. Weder, M. Joerger, D. C. Betticher, R. A. Stahel and A. Ziegler, Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy, J Clin Oncol 22 (2004), 4157-4164.
41. S. Geiger, S. Holdenrieder, P. Stieber, G. F. Hamann, R. Brüning, J. Ma, D. Nagel and D. Seidel, Nucleosomes in serum of patients with early cerebral stroke, Cerebro Vasc Dis 21 (2006), 32-37.
42. S. Geiger, S. Holdenrieder, P. Stieber, G. F. Hamann, R. Bruening, J. Ma, D. Nagel and D. Seidel, Nucleosomes as a new prognostic marker in early cerebral stroke, J Neurol 254 (2007), 617-623.
43. L. Giovanella, L. Ceriani, M. Bandera, R. Rimoldi, B. Beghe and G. Roncari, Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non small cell lung cancer evaluation, Q J Nucl Med 39 (1995), 285-289.
44. L. Giovanella, R. Piantanida, L. Ceriani, M. Bandera, R. Novario, L. Bianchi and G. Roncari, Immunoassay of neuronspecific enolase (NSE) and serum fragments of cytokeratin 19 (CYFRA 21.1) as tumor markers in small cell lung cancer: clinical evaluation and biological hypothesis, Int J Biol Markers 12 (1997), 22-26.
45. L. Giovanella, L. Ceriani, G. Giardina, D. Bardelli, F. Tanzi and S. Garancini, Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA), Clin Chem Lab Med 40 (2002), 298-303.
46. L. Goyal, Cell death inhibition: keeping caspases in check, Cell 104 (2001), 805-808.
47. D. R. Green and J. C. Reed, Mitochondria and apoptosis, Science 281 (1998), 1309-1313.
48. A. Greystoke, J. Cummings, T. Ward, K. Simpson, A. Renehan, F. Butt, D. Moore, J. Gietema, F. Blackhall, M. Ranson, A. Hughes and C. Dive, Optimisation of circulating biomarkers of cell death for routine clinical use, Ann Oncol 19 (2008), 990-995.
49. A. Hamzaoui, P. Thomas, O. Castelnau, N. Roux, F. Roux and J. P. Kleisbauer, Usefulness of longitudinal evaluation of CYFRA 21-1 variations in advanced lung cancer monitoring, Lung Cancer 16 (1997), 191-202.
50. T. Hara, H. Tsurumi, M. Takemura, H. Goto, T. Yamada, M. Sawada, T. Takahashi and H. Moriwaki, Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma, Am J Hematol 64 (2000), 257-261.
51. U. Hasholzner, L. Baumgartner, P. Stieber, W. Meier, K. Hofmann and A. Fateh-Moghadam, Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma, Anticancer Res 14 (1994), 2743-2746.
52. K. D. Hatzakis, M. E. Froudarakis, D. Bouros, N. Tzanakis, N. Karkavitsas and N. M. Siafakas, Prognostic value of serum tumor markers in patients with lung cancer, Respiration 69 (2002), 25-29.
53. L. Hefler, K. Mayerhofer, A. Nardi, A. Reinthaller, C. Kainz and C. Tempfer, Serum soluble Fas levels in ovarian cancer, Obstet Gynecol 96 (2000), 65-69.
54. M. O. Hengartner, The biochemistry of apoptosis, Nature 407 (2000), 770-776.
55. H. Hentze, F. Schoebel, S. Lund, M. Kehl, W. Ertel, A. Wendel, M. Jäättelä and M. Leist, In vivo and in vitro evidence for extracellular caspase activity released from apoptotic cells, Biochem Biophys Res Commun 283 (2001), 1111-1117.
56. J. G. Herman and S. B. Baylin Gene silencing in cancer in association with promoter hypermethylation, N Engl J Med 349 (2003), 2042-2054.
57. L. J. Herrera, S. Raja, W. E. Gooding, T. El-Hefnawy, L. Kelly, J. D. Luketich and T. E. Godfrey, Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies, Clin Chem 51 (2005), 113-118.
58. S. Holdenrieder, P. Stieber, T. Foerg, M. Kuehl, L. Schulz, M. Busch, A. Schalhorn and D. Seidel, Apoptosis in serum of patients with solid tumours, Anticancer Res 19 (1999), 2721-2724.
59. S. Holdenrieder, P. Stieber, H. Bodenmueller, G. Fertig, H. Fuerst, N. Schmeller, M. Untch and D. Seidel, Nucleosomes in serum as a marker for cell death, Clin Chem Lab Med 39 (2001), 596-605.
60. S. Holdenrieder, P. Stieber, H. Bodenmueller, M. Busch, G. Fertig, H. Fuerst, A. Schalhorn, N. Schmeller, M. Untch and D. Seidel, Nucleosomes in serum of patients with benign and malignant diseases, Int J Cancer 95 (2001), 114-120.
61. S. Holdenrieder and P. Stieber, Apoptotic markers in cancer, Clin Biochem 37 (2004), 605-617.
62. S. Holdenrieder and P. Stieber, Therapy control in oncology by circulating nucleosomes, Ann N Y Acad Sci 1022 (2004), 211-216.
63. S. Holdenrieder, P. Stieber, J. v Pawel, H. Raith, D. Nagel, K. Feldmann and D. Seidel, Circulating nucleosomes predict the response to chemotherapy in patients with advanced non small cell lung cancer, Clin Cancer Res 10 (2004), 5981-5987.
64. S. Holdenrieder, L. Holubec, Jr., O. Topolcan, J. Finek and P. Stieber, Circulating nucleosomes and cytokeratin 19-fragments in patients with colorectal cancer during chemotherapy, Anticancer Res 25 (2005), 1795-1801.
65. S. Holdenrieder, P. Eichhorn, U. Beuers, W. Samtleben, U. Schoenermarck, R. Zachoval, D. Nagel and P. Stieber, Nucleosomal DNA fragments in autoimmune diseases, Ann N Y Acad Sci 1075 (2006), 318-327.
66. S. Holdenrieder, P. Stieber, J. v Pawel, H. Raith, D. Nagel, K. Feldmann and D. Seidel, Early and specific prediction of the therapeutic efficacy in lung cancer by nucleosomal DNA and cytokeratin 19 fragments, Ann N Y Acad Sci 1075 (2006), 244-275.
67. S. Holdenrieder, D. Nagel, V. Heinemann, J. v Pawel, H. Raith, K. Feldmann, U. H. Stenman and P. Stieber, Predictive and prognostic biomarker models in advanced lung cancer, J Clin Oncol 26 (2008), 19010 (Abs).
68. S. Holdenrieder, J. v Pawel, E. Dankelmann, T. Duell, B. Faderl, A. Markus, M. Siakavara, H. Wagner, K. Feldmann, H. Hoffmann, H. Raith, D. Nagel and P. Stieber, Nucleosomes, ProGRP, NSE, CYFRA 21-1 and CEA in the therapy monitoring of small-cell lung cancer during first-line chemotherapy, Clin Cancer Res 14 (2008), 7813-7821.
69. S. Holdenrieder, J. v Pawel, E. Dankelmann, T. Duell, B. Faderl, A. Markus, M. Siakavara, H. Wagner, K. Feldmann, H. Hoffmann, H. Raith, D. Nagel and P. Stieber, Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer, Lung Cancer 63 (2009), 128-135.
70. S. Holdenrieder and P. Stieber, Clinical use of circulating nucleosomes, Crit Rev Lab Med Sci 46 (2009), 1-24.
71. S. Holdenrieder, D. Nagel and P. Stieber, Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer, Cancer Biomark 6 (2010), 179-190.
72. M. S. Huang, s. B. Jong, M. S. Tsai, M. S. Lin, I. W. Chong, H. C. Lin and J. J. Hwang, Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma, Respir Med 91 (1997), 135-142.
73. T. Ichikura, T. Majima, T. Uchida, E. Okura, T. Ogawa and H. Mochizuki, Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma, Oncol Rep 8 (2001), 311-314.
74. T. Ishii, S. Bandoh, J. Fujita, Y. Ohtsuki, Y. Tojo, N. Kanaji, Y. Fukunaga, Y. Ueda, T. Ishida and A. Kubo, Full-length cytokeratin 8 is released and circulates in patients with nonsmall cell lung cancer, Tumour Biol 29 (2008), 57-62.
75. M. Jaattela, Escaping cell death: survival proteins in cancer, Exp Cell Res 248 (1999), 30-43.
76. S. Jahr, H. Hentze, S. Englisch, D. Hardt, F. O. Fackelmayer, R. D. Hesch and R. Knippers, DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells, Cancer Res 61 (2001), 1659-1665.
77. N. Joza, S. A. Susin, E. Daugas, W. L. Stanford, S. K. Cho, C. Y. J. Li, T. Sasaki, A. J. Elia, H. Y. M. Cheng, L. Gavagnan, K. F. Ferri, N. Zamzami, A. Wakeham, R. Hakem, H. Yoshida, Y. Y. Kong, T. W. Mak, J. C. Zuniga-Pfluecker, G. Kroemer and J. M. Penninger, Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death, Nature 410 (2001), 549-554. (Pubitemid 32267191)
78. C. H. Kao, J. F. Hsieh, Y. J. Ho and H. J. Ding, Cytokeratin fragment 19 (CYFRA 21-1) and carcinoembryonic antigen for early prediction of recurrence of lung adenocarcinoma, Lung 177 (1999), 333-337.
79. K. Kashiwabara, H. Nakamura and T. Esaki, Prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma-related antigen and cytokeratin 19 fragment levels, Clin Chim Acta 294 (2000), 105-113.
80. S. Kasimir-Bauer, N. Schleucher, R. Weber, R. Neumann and S. Seeber, Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival, Oncol Rep 10 (2003), 475-482.
81. J. F. Kerr, C. M. Winterford and B. V. Harmon, Apoptosis. Its significance in cancer and cancer therapy, Cancer 73 (1994), 2013-2026.
82. M. Kimura, Y. Tomita, T. Imai, T. Saito, A. Katagiri, T. Tanikawa, M. Takeda and K. Takahashi, Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients, Br J Cancer 80 (1999), 1648-1651.
83. P. J. Koelink, C. B. Lamers, D. W. Hommes and H. W. Verspaget. Circulating cell death products predict clinical outcome of colorectal cancer patients, BMC Cancer 9 (2009), 88.
84. R. Konno, T. Takano, S. Sato and A. Yajima, Serum soluble fas level as a prognostic factor in patients with gynecological malignancies, Clin Cancer Res 6 (2000), 3576-3580.
85. J. J. Koornstra, S.de Jong, H. Hollema, E. G. de Vries and J. H. Kleibeuker, Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature, Crit Rev Oncol Hematol 45 (2003), 37-53.
86. G. Kramer, H. Erdal, H. J. Mertens, M. Nap, J. Mauermann, G. Steiner, M. Marberger, K. Biven, M. C. Shoshan and S. Linder, Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18, Cancer Res 64 (2004), 1751-1756.
87. P. H. Krammer, CD95 (APO-1/Fas)-mediatied apoptosis: live and let die, Adv Immunol 71 (1999), 163-210.
88. P. H. Krammer, CD95's deadly mission in the immune system, Nature 407 (2000), 789-795.
89. L. Kren, J. Brazdil, M. Hermanova, V. N. Goncharuk, B. V. Kallakury, P. Kaur and J. S. Ross, Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases, Appl Immunohistochem Mol Morphol 12 (2004), 44-49.
90. G. Kroemer, The proto-oncogene Bcl-2 and its role in regulating apoptosis, Nature Med 3 (1997), 614-619.
91. J. Kulpa, E. Wojcik, A. Radkowski, L. Kolodziejski and Z. Stasik, CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group, Anticancer Res 20 (2000), 5035-5040.
92. J. Kulpa, E. Wojcik, M. Reinfuss and L. Kolodziejski, Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients, Clin Chem 48 (2002), 1931-1937.
93. S. Kumar, R. Guleria, V. Singh, A. C. Bharti, A. Mohan and B. C. Das, Plasma nucleosome levels might predict response to therapy in patients with advanced non-small-cell lung cancer, Clin Lung Cancer 11 (2010), 36-44.
94. K. Kuroi, C. Tanaka and M. Toi, Plasma nucleosome levels in node-negative breast cancer patients, Breast Cancer 6 (1999), 361-364.
95. K. Kuroi, C. Tanaka and M. Toi, Clinical significance of plasma nucleosomes levels in cancer patients, Int J Oncol 19 (2001), 143-148.
96. C. Kuropkat, B. M. Lippert and J. A. Werner, Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck, Oncology 63 (2002), 280-285.
97. N. E. Kushlinskii, T. A. Britvin, S. G. Abbasova, A. G. Perevoshchikov, V. V. Prorokov, I. A. Kostanyan, V. I. Knysh and V. M. Lipkin, Soluble Fas antigen in the serum of patients with colon cancer, Bull Exp Biol Med 131 (2001), 361-363.
98. R. S. Lai, H. K. Hsu, J. Y. Lu, L. P. Ger and N. S. Lai, CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer, Chest 109 (1996), 995-1000.
99. J. K. Lee, J. F. Hsieh, S. C. Tsai, Y. J. Ho, S. S. Sun and C. H. Kao, Comparison of CYFRA 21-1 and squamous cell carcinoma antigen in detecting nasopharyngeal carcinoma, Ann Otol Rhinol Laryngol 110 (2001), 775-778.
100. M. P. G. Leers, W. Koelgen, V. Bjoerklund, T. Bergman, G. Tribbick, B. Persson, P. Bjoerklund, F. C. S. Ramaekers, B. Bjoerklund, M. Nap, H. Joernvall and B. Schutte, Immunocytochemical detection and mapping of a cytokeratin 18 neoepitope exposed during early apoptosis, J Pathol 187 (1999), 567-572.
101. K. I. Lei, L. Y. Chan, W. Y. Chan, P. J. Johnson and Y. M. D. Lo, Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma, Clin Cancer Res 8 (2002), 29-34.
102. M. Leist and M. Jäätelä, Four deaths and a funeral: From caspases to alternative mechanisms, Nat Rev Mol Cell Biol 2 (2001), 1-10.
103. S. A. Leon, B. Shapiro, D. M. Sklaroff and M. J. Yaros, Free DNA in the serum of cancer patients and the effect of therapy, Cancer Res 37 (1977), 646-650.
104. Q. L. Liang, D. C. Pan, Z. M. Yin, G. X. Liu, Q. Yang, J. R. Xie, L. Z. Cai and Y. W. Fu, Clinical value of serum soluble Apo-1/Fas for predicting biological behaviors and prognosis of gastric carcinoma, Ai Zheng 21 (2002), 174-176.
105. A. V. Lichtenstein, H. S. Melkonyan, L. D. Tomei and S. R. Umansky, Circulating nucleic acids and apoptosis, Ann N Y Acad Sci 945 (2001), 239-249.
106. S. Linder, Cytokeratin markers come of age, Tumour Biol 28 (2007), 189-195.
107. Y. M. D. Lo, L. Y. Chan, K. W. Lo, S. F. Leung, J. Zhang, A. T. Chan, J. C. Lee, N. M. Hjelm, P. J. Johnson and D. P. Huang, Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma, Cancer Res 59 (1999), 1188-1191.
108. Y. M. D. Lo, L. Y. Chan, A. T. Chan, S. F. Leung, K. W. Lo, J. Zhang, J. C. Lee, N. M. Hjelm, P. J. Johnson and D. P. Huang, Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma, Cancer Res 59 (1999), 5452-5455. (Pubitemid 29526455)
109. Y. M. D. Lo, S. F. Leung, L. Y. Chan, A. T. Chan, K. W. Lo, P. J. Johnson and D. P. Huang, Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma, Cancer Res 60 (2000), 2351-2355.
110. Y. M. D. Lo, A. T. Chan, L. Y. Chan, S. F. Leung, C. W. Lam, D. P. Huang and P. J. Johnson, Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA, Cancer Res 60 (2000), 6878-6881.
111. B. B. Ma, S. F. Leungm, E. P. Hui, F. Mo, W. H. Kwan, B. Zee, J. Yuen and A. T. Chan, Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy, Cancer 101 (2004), 776-781.
112. P. C. Mack, W. S. Holland, R. A. Burich, R. Sangha, L. J. Solis, Y. Li, L. A. Beckett, P. N. Lara, Jr., A. M. Davies and D. R. Gandara, EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated nonsmall cell lung cancer, J Thorac Oncol 4 (2009), 1466-1472.
113. A. Maebo, Plasma DNA level as a tumor marker in primary lung cancer, Nihon Kyobu Shikkan Gakkai Zasshi 28 (1990), 1085-1091.
114. S. Maheswaran, L. V. Sequist, S. Nagrath, L. Ulkus, B. Brannigan, C. V. Collura, E. Inserra, S. Diederichs, A. J. Iafrate, D. W. Bell, S. Digumarthy, A. Muzikansky, D. Irimia, J. Settleman, R. G. Tompkins, T. J. Lynch, M. Toner and D. A. Haber, Detection of mutations in EGFR in circulating lungcancer cells, N Engl J Med 359 (2008), 366-377.
115. D. Micha, J. Cummings, A. Shoemaker, S. Elmore, K. Foster, M. Greaves, T. Ward, S. Rosenberg, C. Dive and K. Simpson, Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer, Clin Cancer Res 14 (2008), 7304-7310.
116. Y. Mizutani, F. Hongo, N. Sato, O. Ogawa, O. Yoshida and T. Miki, Significance of serum soluble Fas ligand in patients with bladder carcinoma, Cancer 92 (2001), 287-293.
117. R. Molina, C. Agusti, X. Filella, J. Jo, J. Joseph, N. Gimenez and A. M. Ballesta, Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases, Tumour Biol 15 (1994), 318-325.
118. R. Molina, X. Filella, J. M. Auge, R. Fuentes, I. Bover, J. Rifa, V. Moreno, E. Canals, N. Vinolas, A. Marquez, E. Barreiro, J. Borras and P. Viladiu, Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors, Tumour Biol 24 (2003), 209-218.
119. R. Molina, X. Filella, J. M. Auge, E. Bosch, A. Torne, J. Pahisa, J. A. Lejarcegui, A. Rovirosa, B. Mellado, J. Ordi and A. Biete, CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA, Anticancer Res 25 (2005), 1765-1771.
120. R. Molina, S. Holdenrieder, J. M. Auge, A. Schalhorn, R. A. Hatz and P. Stieber, Diagnostic relevance of circulating biomarkers in patients with lung cancer, Cancer Biomark 6 (2010), 163-178.
121. R. Mouawad, D. Khayat and C. Soubrane, Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma, Melanoma Res 10 (2000), 461-467.
122. R. Mouawad, E. C. Antoine, M. Gil-Delgado, D. Khayat and C. Soubrane, Serum caspase-1 levels in metastatic melanoma patients: relationship with tumour burden and non-response to biochemotherapy, Melanoma Res 12 (2002), 343-348.
123. T. Muley, H. Dienemann and W. Ebert, Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC, Anticancer Res 23 (2003), 4085-4093.
124. R. Munker, A. Younes, F. Cabanillas and M. Andreeff, Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: absence of prognostic correlations, Leuk Lymphoma 27 (1997), 517-521.
125. H. Nakahama, Y. Tanaka, Y. Fujita, M. Fujii and M. Sugita, CYFRA 21-1 and ProGRP, tumor markers of lung cancer, are elevated in chronic renal failure patients, Respirology 3 (1998), 207-210.
126. S. Nagata, Apoptosis by death factor, Cell 88 (1997), 355-365.
127. B. Nakata, Y. S. Chung, Y. Kato, M. Ogawa, Y. Ogawa, A. Inui, K. Maeda, T. Sawada and M. Sowa, Clinical significance of serum CYFRA 21-1 in gastric cancer, Br J Cancer 73 (1996), 1529-1532.
128. B. Nakata, Y. Ogawa, T. Ishikawa, K. Ikeda, Y. Kato, H. Nishino and K. Hirakawa, Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma, Cancer 89 (2000), 1285-1290.
129. K. Nasu, Y. Etoh, J. Yoshimatsu, T. Matsu, H. Narahara and I. Miyakawa, Serum levels of cytokeratin 19 fragments in cervical cancer, Gynecol Obstet Invest 42 (1996), 267-270.
130. E. K. Ng, N. B. Tsui, N. Y. Lam, R. W. Chiu, S. C. Yu, S. C. Wong, E. S. Lo, T. H. Rainer, P. J. Johnson and Y. M. Lo, Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthyindividuals, Clin Chem 48 (2002), 1212-1217.
131. D. W. Nicholson, Caspase structure, proteolytic substrates, and function during apoptotic cell death, Cell Death Differ 6 (1999), 1028-1042.
132. N. Niitsu, K. Sasaki and M. Umeda, A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma, Leukemia 13 (1999), 1434-1440.
133. B. Nisman, J. Lafair, N. Heching, O. Lyass, M. Baras, T. Peretz and V. Barak, Evaluation of tissue polypeptide specific antigen, CYFRA 21-1 and carcinoembryonic antigen, in nonsmall cell lung carcinoma. Does the combined use of cytokeratin markers give any additional information? Cancer 82 (1998), 1850-1859.
134. N. Nonomura, K. Nishimura, Y. Ono, T. Fukui, Y. Harada, N. Takaha, S. Takahara and A. Okuyama, Soluble Fas in serum from patients with renal cell carcinoma, Urology 55 (2000), 151-155. (Pubitemid 30050785)
135. L. M. Osorio, M. Aguilar-Santelises, A. De Santiago, T. Hachiya T H. Mellstedt and M. Jondal, Increased serum levels of soluble Fas in progressive B-CLL, Eur J Haematol 66 (2001), 342-346.
136. B. Ozturk, U. Coskun, B. Sancak, E. Yaman, S. Buyukberber and M. Benekli, Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors. Int Immunopharmacol 9 (2009), 645-648.
137. M. Paci, S. Maramotti, E. Bellesia, D. Formisano, L. Albertazzi, T. Ricchetti, G. Ferrari, V. Annessi, D. Lasagni, C. Carbonelli, S. De Franco, M. Brini, G. Sgarbi and R. Lodi, Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer, Lung Cancer 64 (2009), 92-97.
138. Z. Peng, H. Tang, Y. Ling and G. Han, Apoptosis and Fas system are significantly involved in the process of liver cirrhosis converting into hepatocellular carcinoma, J Tongji Med Univ 21 (2001), 126-129. (Pubitemid 41289799)
139. L. Pignataro, E. Arisi, G. Sambataro and M. M. Corsi, Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment, J Surg Oncol 83 (2003), 112-115.
140. J. L. Pujol, J. Grenier, E. Parrat, M. Lehmann, T. Lafontaine, X. Quantin and F. B. Michel, Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS, Am J Respir Crit Care Med 154 (1996), 725-733.
141. J. L. Pujol, X. Quantin, W. Jacot, J. M. Boher, J. Grenier and P. J. Lamy, Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer, Lung Cancer 39 (2003), 131-138.
142. J. L. Pujol, O. Molinier, W. Ebert, J. P. Daures, F. Barlesi, G. Buccheri, M. Paesmans, E. Quoix, D. Moro-Sibilot, M. Szturmowicz, J. M. Brechot, T. Muley and J. Grenier, CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients, Br J Cancer 90 (2004), 2097-2105. (Pubitemid 38869712)
143. O. Pradier, A. Hille, H. Schmiberger and C. F. Hess, Monitoring of therapy in head and neck patients during the radiotherapy by measurement of Cyfra 21-1, Cancer Radiother 6 (2002), 15-21.
144. E. Pras, P. H. Willemse, A. A. Canrinus, H. W. de Bruijn, W. J. Sluiter, K. A. ten Hoor, J. G. Aalders, B. G. Szabo and E. G. de Vries, Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment, Int J Radiat Oncol Biol Phys 52 (2002), 23-32.
145. P. Ray, X. Quantin, J. Grenier and J. L. Pujol, Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy, Cancer Detect Prev 22 (1998), 293-304.
146. J. C. Reed, Dysregulation of apoptosis in cancer, J Clin Oncol 17 (1999), 2941-2953.
147. T. Rich, R. L. Allen and A. H. Wyllie, Defying death after DNA damage, Nature 407 (2000), 777-783.
148. P. Rumore, B. Muralidhar, M. Lin, C. Lai and C. R. Steinman, Hemodialysis as a model for studying endogenous plasma DNA: oligonucleosome-like structure and clearance, Clin Exp Immunol 90 (1992), 56-62.
149. P. Saikumar, Z. Dong, V. Mikhailov, M. Denton and J. M. Weinberg, Venkatachalam MA Apoptosis: definition, mechanisms, and relevance to disease, Am J Med 107 (1999), 489-506.
150. H. R. Salih, S. Holdenrieder and Steinle, Soluble NKG2D ligands: prevalence, release, and functional impact, Front Biosci 13 (2008), 3448-3456.
151. A. Samali, B. Zhivotovsky, D. Jones, S. Nagata and S. Orrenius, Apoptosis: cell death defined by caspase activation, Cell Death Differ 6 (1999), 495-496.
152. C. Scaffidi, S. Fulda, A. Srinivasan, C. Friesen, F. Li, K. J. Tomaselli, K. M. Debatin, P. H. Krammer and M. E. Peter, Two CD95 (APO-1/Fas) signaling pathways, EMBO J 17 (1998), 1675-1687.
153. P. Schaer, Spontaneous DNA damage, genome instability, and cancer-when DNA replication escapes control, Cell 104 (2001), 329-232.
154. A. Schalhorn, H. Fuerst and P. Stieber, Tumor markers in lung cancer, J Lab Med 25 (2001), 353-361.
155. H. Schouwink, C. M. Korse, J. M. Bonfrer, A. A. Hart and P. Baas, Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma, Lung Cancer 25 (1999), 25-32.
156. D. R. Schultz and W. J. Harrington, Apoptosis: programmed cell death at a molecular level, Semin Arthritis Rheum 32 (2003). 345-369.
157. H. Schulze-Bergkamen and P. H. Krammer, Apoptosis in cancer-implications for therapy, Semin Oncol 31 (2004), 90-119.
158. B. Shapiro, M. Chakrabarty, E. M. Cohn and S. A. Leon, Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease, Cancer 51 (1983), 2116-2120.
159. M. A. Sheard, B. Vojtesek, M. Simickova and D. Valik, Release of cytokeratin-18 and-19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis, J Cell Biochem 85 (2002), 670-677.
160. S. M. Sheen-Chen, H. S. Chen, H. L. Eng and W. J. Chen, Circulating soluble Fas in patients with breast cancer, World J Surg 27 (2003), 10-13.
161. M. Shimizu, M. Kondo, Y. Ito, H. Kume, R. Suzuki and K. Yamaki, Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients, Cancer Detect Prev 29 (2005), 175-180.
162. N. Shivapurkar, J. Reddy, P. M. Chaudhary and A. F. Gazdar, Apoptosis and lung cancer: a review, J Cell Biochem 88 (2003), 885-898.
163. J. M. Silva, J. Silva, A. Sanchez, J. M. Garcia, G. Dominguez, M. Provencio, L. Sanfrutos, E. Jareno, A. Colas, P. Espana and F. Bonilla, Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival, Clin Cancer Res 8 (2002), 3761-3766. (Pubitemid 35424767)
164. S. Singhal, A. Vachani, D. Antin-Ozerkis, L. R. Kaiser and S. M. Albelda, Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review, Clin Cancer Res 11 (2005), 3974-3986.
165. G. Sozzi, D. Conte, L. Mariani, S. Lo Vullo, L. Roz, C. Lombardo, M. A. Pierotti and L. Tavecchio, Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients, Cancer Res 61 (2001), 4675-4678.
166. G. Sozzi, D. Conte, M. Leon, R. Ciricione, L. Roz, C. Ratcliffe, E. Roz, N. Cirenei, M. Bellomi, G. Pelosi, M. A. Pierotti and U. Pastorino, Quantification of free circulating DNA as a diagnostic marker in lung cancer, J Clin Oncol 21 (2003), 3902-3908.
167. P. Stieber, U. Hasholzner, H. Bodenmueller, D. Nagel, L. Sunder-Plassmann, H. Dienemann, W. Meier and A. Fateh-Moghadam, CYFRA 21-1. A new marker in lung cancer, Cancer 72 (1993), 707-713. (Pubitemid 23215254)
168. P. Stieber, H. Dienemann, U. Hasholzner, P. G. Fabricius, C. Schambeck, M. Weinzierl, S. Poley, W. Samtleben, K. Hofmann, W. Meier, et al. Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases, Int J Biol Markers 9 (1994), 82-88.
169. P. Stieber and V. Heinemann, Sensible use of tumor markers, J Lab Med 32 (2008). 339-360.
170. S. S. Sun, J. F. Hsieh, S. C. Tsai, Y. J. Ho, J. K. Lee and C. H. Kao, Cytokeratin fragment 19 and squamous cell carcinoma antigen for early prediction of recurrence of squamous cell lung carcinoma, Am J Clin Oncol 23 (2000), 241-243.
171. V. Swarup and M. R. Rajeswari, Circulating (cell-free) nucleic acids-a promising, non-invasive tool for early detection of several human diseases, FEBS Lett 581 (2007), 795-799.
172. C. J. Tai, F. Y. Liu, J. A. Liang, S. N. Yang, M. H. Tsai and C. H. Kao, Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma, Anticancer Res 22 (2002), 3793-3796.
173. Y. Takei, K. Minato, S. Tsuchiya, A. Takise, H. Nakano, K. Ezawa, N. Fueki, H. Hoshino, I. Naruse, T. Nomoto, T. Makimoto, S. Ishihara, R. Saito and M. Mori, CYFRA 21-1: an indicator of survival and therapeutic effect in lung cancer, Oncology 54 (1997), 43-47.
174. F. Tas, D. Duranyildiz, H. Oguz, H. Camlica, E. N. Oral, V. Yasasever and E. Topuz, The value of serum bcl-2 levels in advanced lung cancer patients, Med Oncol 22 (2005), 139-144.
175. F. Tas, D. Duranyildiz, H. Oguz, H. Camlica, V. Yasasever and E. Topuz, Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer, Cancer Invest 24 (2006), 576-580. (Pubitemid 44422920)
176. G. Tramonti, M. Ferdeghini, C. Donadio, M. Norpoth, C. Annichiarico, R. Bianchi and C. Bianchi, Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia, Cancer Detect Prev 24 (2000), 86-90.
177. C. Trejo-Becerril, E. Perez-Cardenas, H. Trevino-Cuevas, L. Taja-Chayeb, P. Garcia-Lopez, B. Segura-Pacheco, A. Chavez-Blanco, M. Lizano-Soberon, A. Gonzales-Fierro, I. Mariscal, T. Wegman-Ostrosky and A. Duenas-Gonzalez, Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients, Int J Cancer 104 (2003), 663-668.
178. C. Trejo-Becerril, L. F. Onate-Ocana, L. Taja-Chayeb, A. Vanoye-Carlo, L. Cetina and A. Duenas-Gonzalez, Serum nucleosomes during neoadjuvant chemotherapy in cervical cancer patients. Predictive and prognostic significance, BMC Cancer 5 (2005), 65.
179. S. C. Tsai, C. H. Kao and S. J. Wang, Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen, Neoplasma 43 (1996), 27-29.
180. S. Tsutsumi, H. Kuwano, T. Shimura, N. Morinaga, E. Mochiki and T. Asao, Circulating soluble Fas ligand in patients with gastric carcinoma, Cancer 89 (2000), 2560-2564.
181. T. Uenishi, S. Kubo, K. Hirohashi, H. Tanaka, T. Shuto, T. Yamamoto and S. Nishiguchi, Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer, Br J Cancer 88 (2003), 1894-1899.
182. T. Ueno, M. Toi and T. Tominaga, Circulating soluble Fas concentration in breast cancer patients, Clin Cancer Res 5 (1998), 3529-3533.
183. T. Ueno, M. Toi, K. Biven, H. Bando, T. Ogawa and S. Linder, Measurement of an apoptotic product in the sera of breast cancer patients, Eur J Cancer 39 (2003), 769-774.
184. S. Ugurel, G. Rappl, W. Tilgen and U. Reinhold, Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients, Clin Cancer Res 7 (2001), 1282-1286.
185. E. Ulukaya, A. Yilmaztepe, S. Akgoz, S. Linder and M. Karadag, The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival, Lung Cancer 56 (2007), 399-404.
186. A. Van der Gaast, C. H. Schoenmakers, T. C. Kok, B. G. Blijenberg, F. Cornilllie and T. A. Splinter, Evaluation of a new tumour marker in patients with non-small-cell lung cancer: CYFRA 21-1, Br J Cancer 69 (1994), 525-528.
187. A. M. Verhagen, P. G. Ekert, M. Pakusch, J. Silke, L. M. Connolly, G. E. Reid, R. L. Moritz, R. J. Simpson and D. L. Vaux, Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins, Cell 102 (2000), 43-53.
188. R. T. Vollmer, R. Govindan, S. L. Graziano, G. Gamble, J. Garst, M. J. Kelley and R. H. Christenson, Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response, Clin Cancer Res 9 (2003), 1728-1733.
189. S. Wang, T. An, J. Wang, J. Zhao, Z. Wang, M. Zhuo, H. Bai, L. Yang, Y. Zhang, X. Wang, J. Duan, Y. Wang, Q. Guo and M. Wu, Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non-Small Cell Lung Cancer, Clin Cancer Res 16 (2010), 1324-1330.
190. T. H. Ward, J. Cummings, E. Dean, A. Greystoke, J. M. Hou, A. Backen, M. Ranson and C. Dive, Biomarkers of apoptosis, Br J Cancer 99 (2008), 841-846.
191. B. Wollenberg, V. Jan, U. M. Schmitt, K. Hofmann, P. Stieber and A. Fateh-Moghadam, CYFRA 21-1 is not superior to SCC antigen and CEAinhead andnecksquamouscell cancer, Anticancer Res 16 (1996), 3117-3124.
192. G. S. Xie, A. R. Hou, L. Y. Li, Y. N. Gao and S. J. Cheng, Quantification of plasma DNA as a screening tool for lung cancer, Chin Med J 117 (2004), 1485-1488.
193. K. Yamamoto, M. Oka, H. Hayashi, A. Tangoku, T. Gondo and T. Suzuki, CYFRA 21-1is auseful marker for esophageal squamous cell carcinoma, Cancer 79 (1997), 1647-1655.
194. J. J. Yeh, F. Y. Liu, W. H. Hsu, J. J. Wang, S. T. Ho and A. Kao, Monitoring cytokeratin fragment 19 (CYFRA 21-1) serum levels for early prediction of recurrence of adenocarcinoma and squamous cell carcinoma in the lung after surgical resection, Lung 180 (2002), 273-279.
195. T. Yoshikawa, H. Saito, T. Osaki, S. Matsumoto, S. Tsujitani and M. Ikeguchi, Elevated Fas expression is related to increased apoptosis of circulating CD8+T cell in patients with gastric cancer, J Surg Res 148 (2008), 143-151.
196. T. K. Yung, K. C. Chan, T. S. Mok, J. Tong, K. F. To and Y. M. Lo, Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients, Clin Cancer Res 15 (2009), 2076-2084.
197. U. Zangemeister-Wittke and S. Hopkins-Donaldson, Apoptosis regulation and drug resistance in malignant pleural mesothelioma, Lung Cancer 49 (S1) (2005), S105-S108.
198. A. Ziegler, U. Zangemeister-Wittke and R. A. Stahel, Circulating DNA: a new diagnostic gold mine? Cancer Treatment Rev 28 (2002), 255-271.
199. L. Zitvogel, A. Tesniere and G. Kroemer, Cancer despite immunosurveillance: immunoselection and immunosubversion, Nat Rev Immunol 6 (2006), 715-727.
200. L. Zitvogel, L. Apetoh, F. Ghiringhelli and G. Kroemer, Immunological aspects of cancer chemotherapy, Nat Rev Immunol 8 (2008), 59-73.